Abstracts tagged "ANCA"

Abstract Number: 1083 • 2015 ACR/ARHP Annual Meeting
Nationwide Trends in Hospitalization and in-Hospital Mortality Associated with Granulomatosis with Polyangiitis (GPA)
Zachary Wallace¹, John H. Stone², Hyon K. Choi³, Na Lu³, Sebastian Unizony³ and Eli Miloslavsky⁴, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ³Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Massachusetts General Hopsital, Boston, MA
Background/Purpose: Granulomatosis with polyangiitis (GPA) is associated with severe end-organ damage (e.g., renal failure) and treatment-related complications (e.g., severe infection) which often lead to hospitalization…
Abstract Number: 2278 • 2014 ACR/ARHP Annual Meeting
Orbital Pseudotumor As the Presenting Symptom of Pediatric ANCA-Associated Vasculitis
Amanda Schlefman¹, Maureen Leffler², AnneMarie C. Brescia³ and Carlos D. Rose⁴, ¹A.I. DuPont Hospital for Children, Wilmington, DE, ²Rheumatology, AI duPont Hospital for Children, Wilmington, DE, ³Pediatric Rheumatology, Thomas Jefferson University/ AI duPont Hospital for Children, Wilmington, DE, ⁴Pediatrics, Division of Rheumatology, Nemours A.I. duPont Hospital for Children, Thomas Jefferson University, Wilmington, DE
Background/Purpose: Ocular involvement, particularly orbital pseudotumor, has been reported as the initial manifestation of ANCA-associated vasculitis (AAV) in the adult population, predominantly in granulomatosis with…
Abstract Number: 2186 • 2014 ACR/ARHP Annual Meeting
Clinical and Immunologic Correlates in Cocaine Users with Serum Anti-Neutrophil Cytoplasmic Antibodies
Christian Lood and Grant C. Hughes, Medicine/Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Illicit cocaine use is associated with the development of serum anti-neutrophil cytoplasmic autoantibodies (ANCA) and a variety of clinical manifestations. However, the mechanisms linking…
Abstract Number: 1863 • 2014 ACR/ARHP Annual Meeting
CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Pirow Bekker¹, David Jayne², Annette Bruchfeld³, Matthias Schaier⁴, Kazimierz Ciechanowski⁵, Lorraine Harper⁶, Michel Jadoul⁷, Mårten Segelmark⁸, Daina Selga⁹, Istvan Szombati¹⁰, Michael Venning¹¹, Christian Hugo¹², Paul L. van Daele¹³, Ondrej Viklicky¹⁴, Antonia Potarca¹⁵ and Thomas J. Schall¹⁵, ¹Medical & Clinical Affairs, Chemocentryx, Inc., Mountain View, CA, ²Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ³Karolinska Institute, Stockholm, Sweden, ⁴University of Heidelberg, Heidelberg, Germany, ⁵Pomeranian Medical University, Szczecin, Poland, ⁶Nephrology, University of Birmingham, Birmingham, United Kingdom, ⁷Cliniques Saint-Luc, Brussels, Belgium, ⁸Nephrology, Linkobing University, Linkoping University, Linkoping, Sweden, ⁹Lund University, Lund, Sweden, ¹⁰Budaclinic, Budapest, Hungary, ¹¹Manchester University, Manchester, United Kingdom, ¹²Dresden University, Dresden, Germany, ¹³Erasmus Medical Center, Immunology, Rotterdam, Netherlands, ¹⁴Instit of Clin and Exp Med, Prague, Czech Republic, ¹⁵ChemoCentryx, Inc., Mountain View, CA
Background/Purpose: CCX168 is a potent, specific C5aR inhibitor in clinical development for ANCA-associated vasculitis. The initial focus of this randomized, double-blind, placebo-controlled clinical trial was…
Abstract Number: 1862 • 2014 ACR/ARHP Annual Meeting
The Association of Low-Density Granulocytes with Disease Activity and Response to Treatment in ANCA-Associated Vasculitis
Peter C. Grayson¹, Carmelo Carmona-Rivera¹, Lijing Xu², Noha Lim², Adam Asare², Deborah J. Phippard², Mariana J. Kaplan³, Peter A. Merkel⁴ and Paul A. Monach⁵, ¹NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, ²Immune Tolerance Network, Bethesda, MD, ³Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA
Background/Purpose: To discover new pathways involved in the pathophysiology of ANCA-associated vasculitis (AAV) and identify potential clinical biomarkers through use of whole-genome gene expression profiling.…
Abstract Number: 1777 • 2014 ACR/ARHP Annual Meeting
Staphylococcus Aureus Nasal Carriage and Relapses, Bvas, ANCA-Positivity and Cotrimoxazole Use in ANCA-Associated Vasculitis
Boun Kim Tan¹, Yoann Crabol¹, Jason Tasse^2,3, Frederic Laurent^2,3, Xavier Puechal^4,5, Christine Vinter⁶ and Loïc Guillevin^1,5, ¹Internal Medicine, Hôpital Cochin, University Paris V Descartes, Paris, France, ²Laboratoire de Bactériologie de l'hôpital de la Croix-Rousse, National Reference Centre for Staphylococci, Lyon, France, ³INSERM U1111, CNRS UMR5308, International Centre for Research in Infectious Diseases, Lyon, France, ⁴Internal Medicine, Hôpital Cochin, Paris, France, ⁵French Vasculitis Study Group (FVSG), Paris, France, ⁶Internal Medecine, Hôpital Cochin, Paris, France
Background/Purpose Staphylococcus aureus (SA) nasal carriage has been reported to be more frequent and associated with persistent ANCA-positivity and relapse in patients with granulomatosis with…
Abstract Number: 1776 • 2014 ACR/ARHP Annual Meeting
Factors Predictive of ANCA-Associated Vasculitis Relapse in Patients Given Rituximab-Maintenance Therapy
Benjamin Terrier¹, Christian Pagnoux², Guillaume Geri³, Alexandre Karras⁴, Chahéra Khouatra⁵, Olivier Aumaitre⁶, Pascal Cohen⁷, Francois Maurier⁸, Olivier Decaux⁹, Hélène Desmurs-Clavel¹⁰, Pierre Gobert¹¹, Thomas Quemeneur¹², Claire Blanchard-Delaunay¹³, Pascal Godmer¹⁴, Xavier Puéchal⁷, Luc Mouthon⁷ and Loïc Guillevin for the French Vasculitis Study Group⁷, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ³Intensive Care Unit, Cochin Hospital, Paris, France, ⁴Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁵CHU Louis Pradel, Lyon, Lyon, France, ⁶Internal Medicine, CHU, Clermont-Ferrand, France, ⁷National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁸HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁹Department of Internal Medicine, Rennes University Hospital, Rennes, France, ¹⁰University of Lyon, LYON, France, ¹¹Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹²Internal Medicine, CH, Valenciennes, France, ¹³Internal Medicine, Hôpital de Niort, Niort, France, ¹⁴Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France
Background/Purpose Rituximab (RTX) was shown to be as effective as cyclophosphamide to induce remission in patients with ANCA-associated vasculitis (AAV). The prospective MAINRITSAN trial compared…
Abstract Number: 1775 • 2014 ACR/ARHP Annual Meeting
Predicting Relapse in Patients with Granulomatosis with Polyangiitis – the Potential Use of Monitoring in Vitro ANCA Production
Judith Land¹, Wayel H. Abdulahad¹, Coen A. Stegeman², Peter Heeringa³ and Abraham Rutgers¹, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Nephrology, University Medical Center Groningen, Groningen, Netherlands, ³Pathology and Medical Biology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose Patients with granulomatosis with polyangiitis (GPA) suffer from frequent disease relapses, with up to 50% of patients relapsing within 5 years. Several risk factors…
Abstract Number: 1773 • 2014 ACR/ARHP Annual Meeting
Otolaryngologic Lesions Are Not Rare and Closely Related with Pachymeningitis and Cranial Neuropathy in MPO-ANCA Associated Vasculitis
Takahiro Nunokawa¹, Naoto Yokogawa², Kota Shimada¹ and Shoji Sugii², ¹Department of Rheumatic diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ²Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan
Background/Purpose: Recently several case reports of serous otitis media (SOM), hypertrophic pachymeningitis (HP) and cranial neuropathy (CN) have been reported in connection with MPO-ANCA associated…
Abstract Number: 1766 • 2014 ACR/ARHP Annual Meeting
Comparison of Clinicopathologically- and Serologically-Based Classification Systems for ANCA-Associated Vasculitis
Sebastian Unizony¹, Eli M. Miloslavsky¹, Miguel Villarreal², Peter A. Merkel³, Paul Monach⁴, E. William St. Claire⁵, Cees Kallenberg⁶, David Ikle², Robert F. Spiera⁷, Nadia Tchao⁸, Deborah J. Phippard⁸, Linna Ding⁹, Carol A. Langford¹⁰, Philip Seo¹¹, Gary S. Hoffman¹², John H. Stone¹ and Ulrich Specks¹³, ¹Rheumatology, Massachusetts General Hospital, Boston, MA, ²Rho, Chapel Hill, NC, ³University of Pennsylvania, Philadelphia, PA, ⁴Rheumatology, Boston University, Boston, MA, ⁵Rheumatology, Duke University School of Medicine, Durham, NC, ⁶Rheumatology and Clinical Immunology, University of Groningen, Groningen, Netherlands, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Immune Tolerance Network, Bethesda, MD, ⁹NIAID, Bethesda, MD, ¹⁰Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ¹¹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹²Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ¹³Frederichs Dr NW, Mayo Clinic, Rochester, MN
Background/Purpose Genome-wide association studies suggest that PR3-ANCA-positive ANCA-associated vasculitis (AAV) is genetically distinct from MPO-ANCA AAV. We evaluated patients enrolled in the RAVE trial according…
Abstract Number: 1765 • 2014 ACR/ARHP Annual Meeting
Comparison of Clinical Characteristics of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis By the Serotype Specificity to Myeloperoxidase and Proteinase-3
Takamasa Murosaki, Takeo Sato, Yoichiro Akiyama, Katsuya Nagatani and Seiji Minota, Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan
Background/Purpose: To correlate the clinical characteristics of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) with myeloperoxidase (MPO)-ANCA and proteinase-3 (PR3)-ANCA, and to detect clinical characteristics of…
Abstract Number: 1783 • 2014 ACR/ARHP Annual Meeting
The Importance of Histopathological Classification of ANCA-Associated Glomerulonephritis in Renal Function and Renal Survival
Valeria Scaglioni¹, Marina Scolnik¹, Luis J. Catoggio¹, Carlos Federico Varela², Gustavo Greloni², Silvia Christiansen³ and Enrique R. Soriano¹, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Nephrology Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Pathology Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose : Histological changes in renal biopsy are the gold standard for establishing the diagnosis of antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (GN). In 2010 a…
Abstract Number: 1755 • 2014 ACR/ARHP Annual Meeting
Proteomic Analysis of ANCA Vasculitis Serum Reveals Broad Neutrophil Activation, Angiogenesis, and Selective Inflammatory Pathway Activation
Melissa Parker, David Gold, Koustubh Ranade and Ethan Grant, Translational Sciences, MedImmune, LLC, Gaithersburg, MD
Background/Purpose ANCA vasculitis is characterized by the presence of autoantibodies directed against MPO, PR3 and other neutrophil proteins. Binding of these autoantibodies to activated neutrophils…
Abstract Number: 1754 • 2014 ACR/ARHP Annual Meeting
Peripheral CD5⁺b-Cells in ANCA-Associated Vasculitis
Sebastian Unizony¹, Noha Lim², Vincent Carey³, Deborah J. Phippard², Nadia Tchao², Eli M. Miloslavsky⁴, Peter A. Merkel⁵, Paul Monach⁶, William St. Clair⁷, Robert F. Spiera⁸, Adam Asare², Philip Seo⁹, Carol A. Langford¹⁰, Gary S. Hoffman¹¹, Cees Kallenberg¹², Ulrich Specks¹³ and John H. Stone⁴, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Immune Tolerance Network, Bethesda, MD, ³Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Massachusetts General Hospital, Boston, MA, ⁵Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁶Rheumatology, Boston University, Boston, MA, ⁷Rheumatology and Immunology, Duke University, Durham, NC, ⁸Rheumatology, Hospital for Special Surgery, New York, NY, ⁹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹⁰Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ¹¹Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, ¹²Rheumatology and Clinical Immunology, University of Groningen, Groningen, Netherlands, ¹³Frederichs Dr NW, Mayo Clinic, Rochester, MN
Background/Purpose We explored the utility of peripheral CD19+ CD5+ B-cells (CD5+ B-cells) as biomarkers in ANCA-associated vasculitis (AAV) Methods CD5+ B-cells were measured longitudinally by…
Abstract Number: 1764 • 2014 ACR/ARHP Annual Meeting
Clinical and Other Differences Observed Between Cocaine Induced and Non-Cocaine Induced Anti-Neutrophil Cytoplasmic Antibody Positive Vasculitis
Santhi Penmetsa¹, N. Suzanne Emil², Joshua Duchesne¹, Wilmer Sibbitt Jr.³, Arthur Bankhurst⁴ and Roderick Fields⁵, ¹Rheumatology, University of New Mexico Health sciences center, Albuquerque, NM, ²Rheumatology, Presbyterian Medical Group, Rio Rancho, NM, ³Rheumatology, University of New mexico health sciences center, Albuquerque, NM, ⁴Rheum/ MSC 105550, University of NM Med Ctr, Albuquerque, NM, ⁵Division of Rheumatology, University of New Mexico health Sciences center, Albuquerque, NM
Background/Purpose Objective: To compare various factors including clinical manifestations, laboratory data and mortality in between two groups of patients with anti-neutrophil cytoplasmic antibody (ANCA) positive…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].